ATRA earnings

U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving ma

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead p

EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS Phase 1 Study of ATA2271 Enrollment Resumed Conference Call and Webcast Today at 1:30 p.m. PST / 4:30 p.m. EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcom

Live Conference Call and Webcast at 4:30 p.m. EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2022 financial results after market close on Tuesday, November 8, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EST to discuss the Company's financial results and provide a corporate update. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 2

Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023 FDA Recommended Pathway to Potential Tab-cel BLA Filing Without Need for New Clinical Trial; European Commission Approval on Track for Q4 2022 ATA3219 on Track for Q4 2022 IND Submission Conference Call and Webcast Today at 1:30 p.m. PDT / 4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune d

Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company's financial results and provide a corporate update. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201

 Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment   IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023 Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced completion of the planned Interim Analysis (IA) of the ATA188 Phase 2 randomized, placebo-controlled study (EMBOLD) in June 2022. The IA included rev

Live Conference Call and Webcast at 5:00 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. EDT. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for internationa

FDA Fast-Track Designated ATA188 Interim Analysis On-Track for June 2022 Tab-cel Anticipated European Commission Approval On-Track for Q4 2022; Dialogue with FDA Ongoing Cash Expected to Fund Planned Operations into Q4 2023 with Sale of Cell Therapy Manufacturing Facility to FUJIFILM for USD 100 Million Conference Call and Webcast Today at 1:30 p.m. PDT/4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catal

Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2022 financial results after market close on Thursday, May 5, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company's financial results and provide a corporate update. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-6

Scientific Experts Join Atara Management Team to Discuss Role of EBV in MS and Clinical Development of ATA188 Live Conference Call and Webcast on March 22 at 4:00 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 – 6:00 p.m. EDT. Dr. Pascal Touchon, President and Chief Executive Officer along with other members of the Atara management team, will present a comprehensive overview of several topics including: EBV a

Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment ATA188 Granted FDA Fast Track Designation in Both Non-Active PPMS and Non-Active SPMS with Phase 2 EMBOLD Study Interim Analysis Planned for Q2 2022 Entered Long-Term Strategic Manufacturing Partnership with Fujifilm with Upfront Cash Payment of USD 100 Million Conference Call and Webcast Today at 1:30 p.m. PST/ 4:30 p.m. EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients wi

Live Conference Call and Webcast at 4:30 p.m. EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EST to discuss the Company's financial results and provide a corporate update. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domesti

Fujifilm to Acquire Atara's Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing Transaction Expected to Result in Reduced Operating Expenses for Atara Upon Closing, Atara's Cash Expected to Fund Planned Operations into Q4 2023 Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered i

Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel® to be Highlighted as Oral Presentation at Upcoming American Society of Hematology Meeting Significant Tab-cel® Regulatory Progress with Imminent EU MAA Submission and Additional Clarity on FDA Requirements for BLA Submission Planned for Q2 2022 ATA188 Data Demonstrates Durable, Clinically Meaningful Disability Improvement and Possible Remyelination in Patients with Progressive Multiple Sclerosis Company to Host Live Conference Call and Webcast Today at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV)

Live Conference Call and Webcast at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EDT to discuss the Company's financial results and provide a corporate update. Analysts and investors can participate in the conference call by dialing 888-437-3179 for domestic callers and

Patients who Achieved Sustained Expanded Disability Status Scale (EDSS) Improvement at any Time Showed Significant Increase in Magnetization Transfer Ratio (MTR) from Baseline at 12 Months, Suggestive of Remyelination 7 of 8 Patients Achieving Sustained Disability Improvement (SDI) Maintained Improvement at all Subsequent Timepoints up to 33 Months, with Most SDI Responses Driven by EDSS Interim Analysis from Randomized Phase 2 EMBOLD Study on Track for H1 2022 Conference Call and Webcast Today, October 13, 2021, at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo

Pierre Fabre to Commercialize Tab-cel® for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Atara to Receive Upfront Payment of USD 45 Million, and Up to Approximately USD 320 Million in Total Milestones, Plus Significant Double-digit Tiered Royalties as a Percentage of Net Sales Atara Retains Full Commercialization Rights to Tab-cel® in the United States and Other Major Markets Tab-cel®, Recently Granted EMA Accelerated Assessment, Remains On-Track for European MAA Filing in November 2021 Atara to Host Conference Call on Monday, October 4 at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and Pierre Fabre today announc

New Magnetization Transfer Ratio (MTR) Imaging Biomarker Data and Two-Year Clinical Data from Open-Label Extension (OLE) Patients Achieving Sustained Expanded Disability Status Scale (EDSS) Improvement Show Increase in MTR at 12 Months Which May Suggest Remyelination Company to Host Live Conference Call and Webcast to Review Full Results on Wednesday, October 13, 2021, at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the Euro

Progress with FDA on evaluating tab-cel® product comparability and new robust Phase 3 ALLELE study data Recent positive milestones with EMA provide clear path for EU Marketing Authorization Application submission in November 2021 Important new ATA188 magnetization transfer ratio (MTR) imaging biomarker data and updated clinical data to be presented at ECTRIMS in October Company to Host Live Conference Call and Webcast Today at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results